BEAN1: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: BEAN1

NCBI ID: G146227

BEAN1

BEAN1: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive neurological disorders that affect millions of people worldwide. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms including cognitive decline, behavioral changes, and motor dysfunction. Despite advances in neuroimaging and disease diagnosis, there is currently no cure for these conditions. The search for new treatments and biomarkers has become a major focus in the field of neurodegenerative diseases, and BEAN1, a protein expressed in the brain associated with NEDD4 1, transcript variant 1, is one such potential drug target and biomarker.

BEAN1: Structure and Function

BEAN1 is a protein that is expressed in the brain and is associated with the neurotransmitter dopamine. It is a member of the NEDD4 gene family, which is known for its role in the production of neurotransmitters, including dopamine. The NEDD4 gene has four splice variants, including BEAN1, which is the most abundant variant. BEAN1 is a 21-kDa protein that consists of 155 amino acid residues. It has a distinct N-terminal region that is involved in its stability and localization to the endoplasmic reticulum (ER). The C-terminus region of BEAN1 contains a putative transmembrane domain and a protein-coding region that is involved in its stability and localization to the ER.

BEAN1 has been shown to play a role in the production of dopamine in the brain. Studies have shown that BEAN1 is involved in the production of dopamine from its precursor, neurotide T, through the use of the enzyme tyrosine hydroxylase (THz). In addition, BEAN1 has been shown to play a role in the regulation of dopamine levels in the brain, by interacting with the dopamine transporter (DAT) and the dopamine receptor (DR).

BEAN1 is also involved in the production of other neurotransmitters, including GABA and serotonin. These interactions with other neurotransmitters suggest that BEAN1 may have a role in the regulation of neurotransmitter homeostasis, and may be a potential drug target for neurodegenerative diseases.

BEAN1: Potential Drug Target

The potential drug target for BEAN1 is the regulation of dopamine levels in the brain. The production of dopamine is a critical regulatory process that is involved in a wide range of brain functions, including motivation, pleasure, and movement. The regulation of dopamine levels is also involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Dopamine is produced in the brain by the neurotransmitter dopamine, which is synthesized from the amino acid tyrosine by the enzyme dopamine oxidase (DO). Tyrosine is converted to tyrosine hydroxylase (THz) by the enzyme tryptophan hydroxylase (THz), which is then converted to dopamine by the enzyme dopamine oxidase (DO).BEAN1 is involved in the production of dopamine from its precursor, neurotide T, through the use of the enzyme tyrosine hydroxylase (THz).

BEAN1 has been shown to play a role in the regulation of dopamine levels in the brain by interacting with the dopamine transporter (DAT) and the dopamine receptor (DR). Studies have shown that BEAN1 interacts with DAT to regulate the uptake and release of dopamine from the axon terminal of dopamine-producing neurons. This interaction between BEAN1 and DAT suggests that BEAN1 may be a useful target for the treatment of neurodegenerative diseases associated with dopamine dysfunction, such as Alzheimer's disease and Parkinson's disease.

BEAN1: Biomarker

BEAN1 is also a potential biomarker for neurodegenerative diseases. The production of dopamine is a critical regulatory process that is involved in

Protein Name: Brain Expressed Associated With NEDD4 1

The "BEAN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BEAN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets